MedTrace Logo

Study to Evaluate the Efficacy of EZC Pak in Adults With Upper Respiratory Infection (URI)

NCT04943575 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2022-04-07

No results posted yet for this study

Summary

A randomized-controlled interventional clinical trial to evaluate the effectiveness of EZC Pak \& EZC Pak+D for the treatment of the common cold and/or a URI.

Conditions

  • Common Cold

Interventions

DIETARY_SUPPLEMENT

EZC Pak

After the onset of common cold symptoms, participants will take one pill (EZC Pak) each day for a period of 5 days.

DIETARY_SUPPLEMENT

EZC Pak +D

After the onset of common cold symptoms, participants will take one pill (EZC Pak +D) each day for a period of 5 days.

DIETARY_SUPPLEMENT

Placebo

After the onset of common cold symptoms, participants will take one pill (Placebo) each day for a period of 5 days.

Sponsors & Collaborators

  • Citruslabs

    collaborator INDUSTRY

  • PPC Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Susanne Mitschke, BSc, MSc · Citruslabs

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2022-01-30
Completion
2022-01-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04943575 on ClinicalTrials.gov